Overview

Study to Evaluate the Safety and Pharmacokinetics of Topically Applied 40% Lidocaine Gel Compared With Placebo in Subjects With Acute Herpes Zoster (Shingles) Pain

Status:
Terminated

Trial end date:
2015-08-01

Target enrollment:

Participant gender:

Summary

Study 2022-HZ-011 will utilize a randomized withdrawal (RW), double-blind, placebo controlled design in which the PK and safety of CNTX 2022 (40% anhydrous lidocaine gel) will be evaluated in subjects with acute-onset herpes zoster pain.

Phase:

Phase 1

Details

Lead Sponsor:

Centrexion Therapeutics

Treatments:

Lidocaine